Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 1/20 | 0.30 |
| ▸ | METAP1 | P53582 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12210431 | 0.75 | CHRNB2 (0.32) | — | |
| SCHEMBL13588387 | 0.73 | ELANE (0.43) | — | |
| SCHEMBL14871071 | 0.72 | GAA (0.31) | GAAL3MBTL1 | |
| SCHEMBL7912750 | 0.71 | CCR1 (0.39) | GAAL3MBTL1 | |
| SCHEMBL13663809 | 0.71 | KDM4E (0.33) | — | |
| SCHEMBL5592626 | 0.68 | SMN1; SMN2 (0.44) | GAAL3MBTL1 | |
| SCHEMBL19054145 | 0.68 | PIK3CA (0.32) | GAAL3MBTL1 | |
| SCHEMBL22799913 | 0.68 | APLNR (0.31) | — | |
| SCHEMBL22323403 | 0.68 | HSD17B3 (0.33) | GAAL3MBTL1 | |
| SCHEMBL19001544 | 0.68 | GAA (0.32) | GAAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4219465-A2 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme Inc (US) | 2023-08-02 | — | — | EP | disclosed |
| EP-3498701-B1 | PRMT5 INHIBITORS AND USES THEREOF | EPIZYME INC (US) | 2023-02-22 | — | — | EP | disclosed |
| US-20230000993-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO INC (US) | 2023-01-05 | — | — | US | disclosed |
| WO-2021110890-A1 | PYRIDINIUM DERIVATIVES AS HERBICIDES | SYNGENTA CROP PROTECTION AG (CH) | 2021-06-10 | — | — | WO | disclosed |
| US-20190290771-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO, INC. | 2019-09-26 | — | — | US | disclosed |
| EP-2935247-B1 | PRMT5 INHIBITORS AND USES THEREOF | EPIZYME INC (US) | 2019-08-28 | — | — | EP | disclosed |
| EP-3498701-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme Inc (US) | 2019-06-19 | — | — | EP | disclosed |
| US-9931407-B2 | Silicon based drug conjugates and methods of using same | BLINKBIO, INC. (US) | 2018-04-03 | — | — | US | disclosed |
| EP-2935243-B1 | PRMT5 INHIBITORS CONTAINING A DIHYDRO- OR TETRAHYDROISOQUINOLINE AND USES THEREOF | EPIZYME INC (US) | 2018-03-14 | — | — | EP | disclosed |
| US-20170334861-A1 | TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-11-23 | — | — | US | disclosed |
| EP-1918312-A1 | Diene polymerisation | INEOS EUROPE LIMITED (GB) | 2008-05-07 | — | — | EP | disclosed |
| EP-1918311-A1 | Diene polymerisation | INEOS EUROPE LIMITED (GB) | 2008-05-07 | — | — | EP | disclosed |
| US-20070207918-A1 | Polymerisation and Oligomerisation Catalysts | INEOS SALES (UK) LIMITED (GB) | 2007-09-06 | — | — | US | disclosed |
| US-20070207918-A1 | Polymerisation and Oligomerisation Catalysts | INEOS SALES (UK) LIMITED (GB) | 2007-09-06 | — | — | US | disclosed |
| US-20070203209-A1 | Useful indole compounds | IRONWOOD PHARMACEUTICALS, INC. | 2007-08-30 | — | — | US | disclosed |
| US-20070203209-A1 | Useful indole compounds | IRONWOOD PHARMACEUTICALS, INC. | 2007-08-30 | — | — | US | disclosed |
| US-7229943-B2 | Polymerisation and oligomerisation catalysts | INNOVENE EUROPE LIMITED (GB) | 2007-06-12 | — | — | US | disclosed |
| US-7229943-B2 | Polymerisation and oligomerisation catalysts | INNOVENE EUROPE LIMITED (GB) | 2007-06-12 | — | — | US | disclosed |
| WO-2007022501-A2 | USEFUL INDOLE COMPOUNDS | MICROBIA, INC. (US) | 2007-02-22 | — | — | WO | disclosed |
| WO-2007015074-A1 | DIENE POLYMERISATION | INEOS EUROPE LIMITED (GB) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190290771-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | CD44, MSN, AS3MT | METAP2 1485/4885METAP1 1280/4885GAA 36/4885 |
| US-20230000993-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | CD44, MSN, AS3MT | METAP2 1485/4885METAP1 1280/4885GAA 36/4885 |
| US-20170334861-A1 | TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT3 | METAP2 3078/4885METAP1 2250/4885GAA 3369/4885 |
| US-20070203209-A1 | Useful indole compounds | TPH2, HRH2, HRH1 | METAP2 427/4885METAP1 1049/4885GAA 3213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.